RenaSci provides an integrated blend of consultancy and experimental services to clients from all sectors of the pharmaceutical industry to help maximise research productivity and streamline drug development. Since the company was established in 2001, we have specialised in abuse/dependence testing and in the therapeutic areas of CNS and metabolic disorders - our core areas of expertise. Our clients include pharma, biotech and virtual companies and healthcare investors from the UK, mainland Europe, USA and Japan and we collaborate with them on all stages of the drug development process from target identification to post registration. Our regulatory expertise combined with skills in drug development and abuse liability assessment have been pivotal to the success of clients in achieving European and US drug registrations. We have facilitated more than 30 NCE’s into clinical development and 10 drugs to the market. Working arrangements with our sponsors range from one off fee-for-service studies through to long term FTE arrangements to ensure the continuity of project work. The fact that we have worked with some of our clients for many years and that many of our clients are returning customers is testament to the high quality of our service. Since July 2018 RenaSci has been part of the Sygnature Group of Companies, complementing the services of Sygnature Discovery.